TABLE 4.
Review of patients with discordant IMMY GM ASR and MVista EIA results (n = 3)
| Patient | Age (yr)/sex | Quantitative results (ng/ml) (qualitative results)a |
Purpose of test | Patient history | |
|---|---|---|---|---|---|
| IMMY ASR | MVista EIA | ||||
| 1 | 52/M | 0 (Neg.) | <0.4 (Pos., BLoQ) | Monitoring | Disseminated histoplasmosis Dx in February 2012, receiving prednisone and azathioprine for treatment of frontal orbital inflammatory pseudotumor at time of Dx; remains on itraconazole |
| 2 | 28/F | 0 (Neg.) | 0.64 (Pos.) | Monitoring | Disseminated histoplasmosis Dx in December 2010, receiving adalimumab and azathioprine for Crohn's disease at time of Dx; remains on itraconazole |
| 3 | 68/M | 0 (Neg.) | <0.4 (Pos., BLoQ) | Initial diagnosis | AML s/p allogeneic SCTx in December 2012; pulmonary histoplasmosis Dx in October 2013 by serology (CF Yst., 1:64; H and M bands by ID)b |
a
Dx, diagnosis; Pos., positive; Neg., negative; AML, acute myeloid leukemia; s/p, status post; SCTx, stem cell transplant; CF, complement fixation; Yst., yeast antigen; ID, immunodiffusion; BLoQ, below the limit of quantification.
b
Serological results were finalized 24 h following serum collection, and MVista EIA results were finalized 72 h following urine collection; the two specimens were collected on the same day.